SELLAS Life Sciences (SLS) FCF Margin (2012 - 2022)
SELLAS Life Sciences' (SLS) quarterly FCF Margin came in at 715.0% in Q1 2022, down 53484.0% year-on-year from N/an in Q1 2021, and down 177.36% on a QoQ basis from 257.79% in Q2 2021.
SELLAS Life Sciences (SLS) FCF Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has 7 years of FCF Margin data on file, last reported at 715.0% in Q1 2022.
- On a quarterly basis, FCF Margin fell 53484.0% year-over-year to 715.0% in Q1 2022; TTM through Dec 2022 was 2380.9%, a 203852.0% decrease from a year earlier, with the FY2022 full-year figure at 2380.9%, down 203852.0% from the prior year.
- FCF Margin for Q1 2022 stood at 715.0%, down from 257.79% in the prior quarter.
- Over the last five years, FCF Margin for SLS reached as high as 180.21% in Q4 2020 and fell as low as 715.0% in Q1 2022.
- Historically, FCF Margin has averaged 243.18% across 3 years, with a median of 218.97% in 2021.
- On a YoY basis, FCF Margin climbed as much as 53484 bps in 2022 and fell as far as 53484 bps in 2022.
- Year by year, FCF Margin stood at 180.21% in 2020, then tumbled by 243 bps to 257.79% in 2021, then slumped by 177 bps to 715.0% in 2022.
- Per Business Quant data, the three most recent FCF Margin figures were 715.0% in Q1 2022, 257.79% in Q2 2021, and 180.16% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -715.00% |
| Jun 30, 2021 | -257.79% |
| Mar 31, 2021 | -180.16% |
| Dec 31, 2020 | 180.21% |
| Jun 30, 2015 | -368.21% |
| Mar 31, 2015 | -399.89% |
| Dec 31, 2014 | -336.24% |
| Sep 30, 2014 | -687.28% |
| Jun 30, 2014 | -556.80% |
| Mar 31, 2014 | -371.38% |
| Dec 31, 2013 | -81.53% |
| Sep 30, 2013 | -499.20% |
| Jun 30, 2013 | -305.58% |
| Mar 31, 2013 | -245.33% |
| Dec 31, 2012 | 442.56% |
| Sep 30, 2012 | -355.98% |